# Bruce A C Cree,, Mas

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 199 papers | 22,886 citations | 15880 67 h-index | 10129 145 g-index |
| 210 all docs | 210 docs citations | 210 times ranked | 23351 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. Brain, 2023, 146, 645-656. | 3.7 | 15 |
| 2 | Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple Sclerosis Journal, 2022, 28, 429-440. | 1.4 | 40 |
| 3 | Identifying falls remotely in people with multiple sclerosis. Journal of Neurology, 2022, 269, 1889-1898. | 1.8 | 5 |
| 4 | Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Multiple Sclerosis and Related Disorders, 2022, 57, 103352. | 0.9 | 19 |
| 5 | AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356. | 0.9 | 16 |
| 6 | Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. Annals of Neurology, 2022, 91, 268-281. | 2.8 | 39 |
| 7 | Multiple sclerosis: two decades of progress. Lancet Neurology, The, 2022, 21, 211-214. | 4.9 | 16 |
| 8 | COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurology and Therapy, 2022, 11, 741-758. | 1.4 | 18 |
| 9 | Reply to â€œSpinal Cord Atrophy Is a Preclinical Marker of Progressive <scp>MS</scp>â€• Annals of Neurology, 2022, 91, 735-736. | 2.8 | 0 |
| 10 | Cryptococcal Meningitis Reported With Fingolimod Treatment. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, . | 3.1 | 11 |
| 11 | Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540. | 1.4 | 16 |
| 12 | Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1591-1605. | 1.4 | 19 |
| 13 | A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. Multiple Sclerosis and Related Disorders, 2022, 61, 103747. | 0.9 | 5 |
| 14 | Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103793. | 0.9 | 3 |
| 15 | Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104. | 1.8 | 7 |
| 16 | The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis. CNS Drugs, 2022, 36, 703-719. | 2.7 | 18 |
| 17 | Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962. | 1.4 | 16 |
| 18 | Letter to the Editor Regarding â€œNetwork Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 ImmunoglobulinÂG-positive Neuromyelitis Optica Spectrum Disorderâ€• Neurology and Therapy, 2022, 11, 1439-1443. | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1432-1441. | 1.4 | 9 |
| 20 | Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 366-379. | 1.4 | 24 |
| 21 | Retinal <scp>INL</scp> Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. Annals of Neurology, 2021, 89, 192-193. | 2.8 | 14 |
| 22 | Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673. | 0.9 | 20 |
| 23 | Effects of COVID-19 â€œSheltering in Placeâ€•on Activity in People With Multiple Sclerosis. Neurology: Clinical Practice, 2021, 11, e216-e218. | 0.8 | 8 |
| 24 | Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48. | 4.5 | 11 |
| 25 | Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Multiple Sclerosis Journal, 2021, 27, 2052-2061. | 1.4 | 11 |
| 26 | Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 3.1 | 20 |
| 27 | Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2219-2231. | 1.4 | 7 |
| 28 | Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910. | 2.8 | 72 |
| 29 | Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders, 2021, 49, 102695. | 0.9 | 5 |
| 30 | Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844. | 0.9 | 19 |
| 31 | Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, 378-388. | 1.5 | 100 |
| 32 | Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders, 2021, 52, 103010. | 0.9 | 13 |
| 33 | Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology, 2021, 28, 3722-3730. | 1.7 | 12 |
| 34 | Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid. JAMA Neurology, 2021, 78, 1355. | 4.5 | 14 |
| 35 | Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. Brain, 2021, 144, 450-461. | 3.7 | 16 |
| 36 | Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386. | 1.5 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Specific hypomethylation programs underpin B cell activation in early multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 14 |
| 38 | Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997. | 4.9 | 64 |
| 39 | Treatment of Multiple Sclerosis: A Review. American Journal of Medicine, 2020, 133, 1380-1390.e2. | 0.6 | 374 |
| 40 | Gut microbiotaâ€“specific IgA <sup>+</sup> B cells traffic to the CNS in active multiple sclerosis. Science Immunology, 2020, 5, . | 5.6 | 132 |
| 41 | Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, . | 3.1 | 22 |
| 42 | Imaging correlates of visual function in multiple sclerosis. PLoS ONE, 2020, 15, e0235615. | 1.1 | 5 |
| 43 | A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22932-22943. | 3.3 | 119 |
| 44 | Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226. | 1.2 | 14 |
| 45 | Switching to fingolimod in PREFERMS: Effect of treatment history and naÃ¯vety on clinical, MRI and treatment satisfaction outcomesâœ°. Multiple Sclerosis and Related Disorders, 2020, 45, 102346. | 0.9 | 1 |
| 46 | A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040. | 1.5 | 28 |
| 47 | Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615. | | 0 |
| 48 | Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615. | | 0 |
| 49 | Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615. | | 0 |
| 50 | Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615. | | 0 |
| 51 | Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262. | 1.4 | 37 |
| 52 | Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1526-1534. | 1.4 | 49 |
| 53 | Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurology, 2019, 76, 1359. | 4.5 | 129 |
| 54 | Reply to â€œSilent Progression or Bout Onset Progressive Multiple Sclerosis?â€• Annals of Neurology, 2019, 86, 472-473. | 2.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Telomere Length Is Associated with Disability Progression in Multiple Sclerosis. Annals of Neurology, 2019, 86, 671-682. | 2.8 | 41 |
| 56 | Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363. | 6.3 | 433 |
| 57 | Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020. | 4.9 | 191 |
| 58 | Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033. | 4.9 | 184 |
| 59 | Lymphocyte counts and infection rates. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, . | 3.1 | 7 |
| 60 | Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, . | 6.0 | 710 |
| 61 | pRNFL as a marker of disability worsening in the medium/long term in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e533. | 3.1 | 18 |
| 62 | Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 92, 151.2-151. | 1.5 | 0 |
| 63 | A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nature Communications, 2019, 10, 2236. | 5.8 | 65 |
| 64 | Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. JAMA Network Open, 2019, 2, e190570. | 2.8 | 69 |
| 65 | Silent progression in disease activityâ€“free relapsing multiple sclerosis. Annals of Neurology, 2019, 85, 653-666. | 2.8 | 265 |
| 66 | Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology, 2019, 266, 1182-1193. | 1.8 | 61 |
| 67 | Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology, 2019, 32, 365-377. | 1.8 | 73 |
| 68 | Disease-modifying therapies alter gut microbial composition in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e517. | 3.1 | 75 |
| 69 | The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924. | 0.5 | 3 |
| 70 | Rituximab in neurological disease: principles, evidence and practice. Practical Neurology, 2019, 19, 5-20. | 0.5 | 59 |
| 71 | Harnessing electronic medical records to advance research on multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 408-418. | 1.4 | 21 |
| 72 | Longitudinally persistent cerebrospinal fluid B-cells can resist treatment in multiple sclerosis. JCI Insight, 2019, 4, . | 2.3 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis â€“ Commentary. Multiple Sclerosis Journal, 2018, 24, 1161-1162. | 1.4 | 5 |
| 74 | Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 789-800. | 1.5 | 107 |
| 75 | Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018, 90, 777-788. | 1.5 | 406 |
| 76 | Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2018, 90, e1815-e1821. | 1.5 | 123 |
| 77 | Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology, 2018, 90, e254-e260. | 1.5 | 41 |
| 78 | The Gut Microbiome in Neuromyelitis Optica. Neurotherapeutics, 2018, 15, 92-101. | 2.1 | 54 |
| 79 | Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. Brain, 2018, 141, 85-98. | 3.7 | 83 |
| 80 | Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the <scp>INFORMS</scp> study. Annals of Clinical and Translational Neurology, 2018, 5, 346-356. | 1.7 | 17 |
| 81 | Rituximab before and during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e453. | 3.1 | 159 |
| 82 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273. | 6.3 | 684 |
| 83 | SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498. | 1.4 | 19 |
| 84 | Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions. Multiple Sclerosis and Related Disorders, 2018, 26, 255-256. | 0.9 | 0 |
| 85 | Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria. MSystems, 2018, 3, . | 1.7 | 56 |
| 86 | Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877433. | 1.5 | 22 |
| 87 | Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. Multiple Sclerosis and Related Disorders, 2018, 25, 50-56. | 0.9 | 9 |
| 88 | Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?. Journal of Neuro-Ophthalmology, 2018, 38, 258-262. | 0.4 | 0 |
| 89 | Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Annals of Neurology, 2018, 84, 51-63. | 2.8 | 38 |
| 90 | Multiple Sclerosis Genetics. , 2018, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. Journal of Neurology, 2017, 264, 316-326. | 1.8 | 109 |
| 92 | Acute liver injury in a Glatopa-treated patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e368. | 3.1 | 4 |
| 93 | Onset of secondary progressive <scp>MS</scp> after longâ€term rituximab therapy â€“ a case report. Annals of Clinical and Translational Neurology, 2017, 4, 46-52. | 1.7 | 22 |
| 94 | Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 476-480. | 1.0 | 17 |
| 95 | Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet, The, 2017, 390, 2481-2489. | 6.3 | 377 |
| 96 | Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology, 2017, 89, 1584-1593. | 1.5 | 65 |
| 97 | Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10713-10718. | 3.3 | 709 |
| 98 | Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics, 2017, 14, 835-841. | 2.1 | 141 |
| 99 | Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight, 2017, 2, . | 2.3 | 84 |
| 100 | Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review. PLoS ONE, 2016, 11, e0154335. | 1.1 | 156 |
| 101 | Steering through complexity. Current Opinion in Neurology, 2016, 29, 263-271. | 1.8 | 11 |
| 102 | Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4777-4782. | 3.3 | 238 |
| 103 | Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e272. | 3.1 | 31 |
| 104 | Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurology: Genetics, 2016, 2, e87. | 0.9 | 76 |
| 105 | Longâ€term evolution of multiple sclerosis disability in the treatment era. Annals of Neurology, 2016, 80, 499-510. | 2.8 | 331 |
| 106 | Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Annals of Neurology, 2016, 80, 443-447. | 2.8 | 125 |
| 107 | Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. JAMA Neurology, 2016, 73, 795. | 4.5 | 64 |
| 108 | Placebo-controlled study in neuromyelitis opticaâ€"Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872. | 1.4 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 1075-1084. | 6.3 | 379 |
| 110 | Characterizing retinal structure injury in African-Americans with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 7, 16-20. | 0.9 | 12 |
| 111 | Statistical Considerations for an Adaptive Design for a Serious Rare Disease. Therapeutic Innovation and Regulatory Science, 2016, 50, 375-384. | 0.8 | 3 |
| 112 | Inclusion of brain volume loss in a revised measure of â€˜no evidence of disease activityâ€™ (NEDA-4) in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1297-1305. | 1.4 | 228 |
| 113 | Placebo controlled trials in neuromyelitis optica are needed and ethical. Multiple Sclerosis and Related Disorders, 2015, 4, 536-545. | 0.9 | 10 |
| 114 | Reduction of CD8 <sup>+</sup> T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e76. | 3.1 | 171 |
| 115 | Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897. | 4.5 | 78 |
| 116 | Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibodyâ€“positive encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e101. | 3.1 | 4 |
| 117 | Fulminant Demyelinating Diseases of the Central Nervous System. Seminars in Neurology, 2015, 35, 656-666. | 0.5 | 17 |
| 118 | Diagnosing Encephalitis, Not Otherwise Specifiedâ€”Reply. JAMA Neurology, 2015, 72, 726. | 4.5 | 0 |
| 119 | An ImmunoChip study of multiple sclerosis risk in African Americans. Brain, 2015, 138, 1518-1530. | 3.7 | 60 |
| 120 | Encephalitis of Unclear Origin Diagnosed by Brain Biopsy. JAMA Neurology, 2015, 72, 66. | 4.5 | 26 |
| 121 | Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815. | 1.5 | 39 |
| 122 | Is TOPIC the last trial for clinically isolated syndrome?. Nature Reviews Neurology, 2015, 11, 6-7. | 4.9 | 1 |
| 123 | Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology, 2015, 262, 326-336. | 1.8 | 20 |
| 124 | Prognostic biomarkers of IFNb therapy in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 894-904. | 1.4 | 20 |
| 125 | Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial. BMC Neurology, 2014, 14, 220. | 0.8 | 30 |
| 126 | MS disease activity in RESTORE. Neurology, 2014, 82, 1491-1498. | 1.5 | 166 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e34. | 3.1 | 61 |
| 128 | Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. Multiple Sclerosis and Related Disorders, 2014, 3, 752. | 0.9 | 13 |
| 129 | Disease Activity Free Status. JAMA Neurology, 2014, 71, 269. | 4.5 | 132 |
| 130 | Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis. JAMA Neurology, 2014, 71, 840. | 4.5 | 57 |
| 131 | Mycophenolate Mofetil to Treat Neuromyelitis Optica. JAMA Neurology, 2014, 71, 1354. | 4.5 | 4 |
| 132 | Acute inflammatory myelopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 613-667. | 1.0 | 23 |
| 133 | 2014 Multiple Sclerosis Therapeutic Update. Neurohospitalist, The, 2014, 4, 63-65. | 0.3 | 3 |
| 134 | Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology, 2014, 76, 568-580. | 2.8 | 158 |
| 135 | In vivo evidence of glutamate toxicity in multiple sclerosis. Annals of Neurology, 2014, 76, 269-278. | 2.8 | 88 |
| 136 | Multiple sclerosis genetics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 193-209. | 1.0 | 44 |
| 137 | Precision medicine in chronic disease management: The multiple sclerosis <scp>B</scp>io<scp>S</scp>creen. Annals of Neurology, 2014, 76, 633-642. | 2.8 | 53 |
| 138 | Genetics of primary progressive multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 211-230. | 1.0 | 17 |
| 139 | Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology, The, 2014, 13, 257-267. | 4.9 | 194 |
| 140 | MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e20. | 3.1 | 24 |
| 141 | Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle and Nerve, 2014, 50, 859-862. | 1.0 | 27 |
| 142 | Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248. | 4.5 | 13 |
| 143 | Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis. Value in Health, 2013, 16, A107. | 0.1 | 2 |
| 144 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360. | 9.4 | 1,213 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Human Molecular Genetics, 2013, 22, 4194-4205. | 1.4 | 81 |
| 146 | Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica. JAMA Neurology, 2013, 70, 629. | 4.5 | 107 |
| 147 | Genetic risk variants in African Americans with multiple sclerosis. Neurology, 2013, 81, 219-227. | 1.5 | 54 |
| 148 | Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 835-843. | 1.4 | 64 |
| 149 | Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies. Seminars in Neurology, 2012, 32, 097-113. | 0.5 | 91 |
| 150 | Neuromyelitis optica following human papillomavirus vaccination. Neurology, 2012, 79, 285-287. | 1.5 | 47 |
| 151 | Aquaporin 4â€specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Annals of Neurology, 2012, 72, 53-64. | 2.8 | 281 |
| 152 | B cell exchange across the blood-brain barrier in multiple sclerosis. Journal of Clinical Investigation, 2012, 122, 4533-4543. | 3.9 | 211 |
| 153 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219. | 13.7 | 2,400 |
| 154 | Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. Journal of Clinical Neuroscience, 2011, 18, 997-998. | 0.8 | 77 |
| 155 | Is there a role for planned natalizumab dosage suspension in mitigating progressive multifocal leukoencephalopathy risk?. Neurodegenerative Disease Management, 2011, 1, 11-14. | 1.2 | 0 |
| 156 | Efficacy of Natalizumab Therapy in Patients of African Descent With Relapsing Multiple Sclerosis. Archives of Neurology, 2011, 68, 464. | 4.9 | 38 |
| 157 | Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology, 2011, 76, 686-692. | 1.5 | 225 |
| 158 | Vitamin D in African Americans with multiple sclerosis. Neurology, 2011, 76, 1824-1830. | 1.5 | 67 |
| 159 | Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy. PLoS ONE, 2011, 6, e16664. | 1.1 | 51 |
| 160 | DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 19-36. | 0.4 | 5 |
| 161 | Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Human Molecular Genetics, 2010, 19, 953-962. | 1.4 | 108 |
| 162 | Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. General Hospital Psychiatry, 2010, 32, 648.e5-648.e8. | 1.2 | 953 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Pilot trial of lowâ€dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology, 2010, 68, 145-150. | 2.8 | 90 |
| 164 | Natalizumab dosage suspension: Are we helping or hurting?. Annals of Neurology, 2010, 68, 395-399. | 2.8 | 108 |
| 165 | IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity, 2010, 11, 397-405. | 2.2 | 70 |
| 166 | A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01. PLoS ONE, 2010, 5, e11296. | 1.1 | 60 |
| 167 | Refining the association of MHC with multiple sclerosis in African Americans. Human Molecular Genetics, 2010, 19, 3080-3088. | 1.4 | 35 |
| 168 | Does race matter for multiple sclerosis?. Neurology, 2010, 74, 532-533. | 1.5 | 10 |
| 169 | Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1201-8. | 4.9 | 82 |
| 170 | Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2010, 292, 28-35. | 0.3 | 56 |
| 171 | Genotypeâ€“Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain, 2009, 132, 250-259. | 3.7 | 154 |
| 172 | Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology, 2009, 72, 1760-1765. | 1.5 | 64 |
| 173 | Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1002-1005. | 0.9 | 103 |
| 174 | Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18680-18685. | 3.3 | 231 |
| 175 | Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778. | 1.4 | 419 |
| 176 | Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Archives of Neurology, 2009, 66, 226-33. | 4.9 | 92 |
| 177 | Neuromyelitis optica: Diagnosis, pathogenesis, and treatment. Current Neurology and Neuroscience Reports, 2008, 8, 427-433. | 2.0 | 54 |
| 178 | F.36. Introduction of a Cell-based Assay Against Native Aquaporin-4-High Specificity and Sensitivity for Neuromyelitis Optica. Clinical Immunology, 2008, 127, S54-S55. | 1.4 | 0 |
| 179 | Treatment of Neuromyelitis Optica With Rituximab. Archives of Neurology, 2008, 65, 1443. | 4.9 | 445 |
| 180 | Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology, 2008, 71, 1390-1395. | 1.5 | 119 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis. Journal of Immunology, 2008, 181, 5473-5480. | 0.4 | 105 |
| 182 | Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. New England Journal of Medicine, 2007, 357, 851-862. | 13.9 | 1,529 |
| 183 | Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology, 2006, 67, 176-177. | 1.5 | 41 |
| 184 | Emerging Monoclonal Antibody Therapies for Multiple Sclerosis. Neurologist, 2006, 12, 171-178. | 0.4 | 44 |
| 185 | Multifactor dimensionality reduction reveals geneâ€“gene interactions associated with multiple sclerosis susceptibility in African Americans. Genes and Immunity, 2006, 7, 310-315. | 2.2 | 52 |
| 186 | Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics, 2006, 15, 2813-2824. | 1.4 | 279 |
| 187 | Interferon Beta-1a Treatment and African Americansâ€”Reply. Archives of Neurology, 2006, 63, 628. | 4.9 | 0 |
| 188 | Characterizing the Mechanisms of Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1345. | 4.9 | 105 |
| 189 | A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nature Genetics, 2005, 37, 1113-1118. | 9.4 | 243 |
| 190 | An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005, 64, 1270-1272. | 1.5 | 607 |
| 191 | Acute transverse myelitis: Is the "idiopathic" form vanishing?. Neurology, 2005, 65, 1857-1858. | 1.5 | 21 |
| 192 | Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30. | 4.9 | 36 |
| 193 | Response to Interferon Beta-1a Treatment in African American Multiple Sclerosis Patients. Archives of Neurology, 2005, 62, 1681. | 4.9 | 76 |
| 194 | Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. Journal of Allergy and Clinical Immunology, 2005, 116, 453-459. | 1.5 | 70 |
| 195 | Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 2004, 63, 2039-2045. | 1.5 | 275 |
| 196 | Linkage and association with theNOS2A locus on chromosome 17q11 in multiple sclerosis. Annals of Neurology, 2004, 55, 793-800. | 2.8 | 60 |
| 197 | Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans. American Journal of Human Genetics, 2004, 74, 160-167. | 2.6 | 311 |
| 198 | Neuromyelitis Optica. Seminars in Neurology, 2002, 22, 105-122. | 0.5 | 128 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis. Frontiers in Neurology, 0, 13, . | 1.1 | 4 |